[Venous thrombo-embolic disease in cancer. Low molecular weight heparin indications]

Abstract

Cancer and venous thrombo-embolic disease (VTE) are closely related. Indeed, cancer can reveal VTE and VTE can be the first sign of cancer. Low molecular weight heparin (LWMH) is now the first line treatment in cancer patients. Compliance with marketing authorizations and guidelines are crucial for patient-centered decision-making. This work deals with the prescription of LWMH in patients who develop VTE during cancer in order to better recognize what should or should not be done. The patient's wishes must be taken into consideration when making the final therapeutic decision. The other treatments are discussed: vitamin K antagonists and direct oral anticoagulants (DOACs) may be useful.

Keywords: Cancer; Héparines de bas poids moléculaire; Low molecular weight heparin; Maladie veineuse thrombo-embolique; Venous thrombo-embolism.